Video

Dr. O'Brien Discusses Combination Venetoclax in CLL

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

In June 2018, the FDA granted a full approval of venetoclax for the treatment of patients with CLL regardless of 17p deletion, and following at least 1 prior therapy. The BCL-2 inhibitor is now also approved for use in combination with rituximab (Rituxan) in the same patient population.

The approval of the combination was based off the phase III MURANO trial, which showed that median follow-up was not reached with venetoclax plus rituximab compared with 18.1 months (95% CI, 15.8-22.3) with bendamustine plus rituximab (HR, 0.19; 95% CI, 0.13-0.28; P <.0001). Overall response rate for venetoclax plus rituximab was 92% compared with 72% for bendamustine plus rituximab.

O’Brien says that now clinicians have the option of treating their patients with single-agent venetoclax, or the combination of venetoclax plus rituximab for 2 years.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center